These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38534028)

  • 1. Improvements of myocardial strain and work in diabetes patients with normal ejection fraction after empagliflozin treatment.
    Cheng X; Huang P; Liu H; Bi X; Gao Y; Lu R; Gao Y; Liu Y; Deng Y
    J Diabetes Investig; 2024 Jul; 15(7):851-860. PubMed ID: 38534028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
    Lan NSR; Yeap BB; Fegan PG; Green G; Rankin JM; Dwivedi G
    Int J Cardiovasc Imaging; 2021 Feb; 37(2):517-527. PubMed ID: 32959096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
    Katogiannis K; Thymis J; Kousathana F; Pavlidis G; Korakas E; Kountouri A; Balampanis K; Prentza V; Kostelli G; Michalopoulou H; Tsilivarakis D; Lambadiari V; Ikonomidis I
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541121
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
    Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
    Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
    Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction.
    Afshani MR; Torfi E; Akiash N; Jahanshahi A; Mohamadi A; Sherafat O
    Acta Cardiol; 2024 Jun; 79(4):419-425. PubMed ID: 38511517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
    Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V
    Cardiovasc Diabetol; 2017 Oct; 16(1):130. PubMed ID: 29025406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELUCIDATE Trial: A Single-Center Randomized Controlled Study.
    Lin JL; Liu SC; Liu TF; Chuang SM; Huang CT; Chen YJ; Lee CC; Chien MN; Hou CJ; Yeh HI; Chiang CE; Hung CL
    J Am Heart Assoc; 2024 May; 13(9):e033832. PubMed ID: 38639353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of using SGLT-2 inhibitor on left ventricular longitudinal strain and NT-proBNP levels during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction.
    Biter HI; Cakal S; Cakal B; Aapaydin Z; Kilinc AY; Oguz H; Yildiz S; Ogur H; Belen E; Simsek E
    Kardiol Pol; 2024; 82(6):640-646. PubMed ID: 38767161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus.
    Hsu JC; Wang CY; Su MM; Lin LY; Yang WS
    Sci Rep; 2019 Oct; 9(1):15348. PubMed ID: 31653956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
    Kräker K; Herse F; Golic M; Reichhart N; Crespo-Garcia S; Strauß O; Grune J; Kintscher U; Ebrahim M; Bader M; Alenina N; Heuser A; Luft FC; Müller DN; Dechend R; Haase N
    Sci Rep; 2020 Aug; 10(1):14061. PubMed ID: 32820187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.